1. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Issue 7 (July 2017) Authors: Clark, Richard E; Polydoros, Fotios; Apperley, Jane F; Milojkovic, Dragana; Pocock, Christopher; Smith, Graeme; Byrne, Jenny L; de Lavallade, Hugues; O'Brien, Stephen G; Coffey, Tony; Foroni, Letizia; Copland, Mhairi Journal: Lancet Issue: Volume 4:Issue 7(2017) Page Start: e310 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗